These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 11841399

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
    Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S.
    Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
    [Abstract] [Full Text] [Related]

  • 4. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC, Hui KM.
    Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
    Poh SL, Linn YC.
    Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y, Bo J, Dai HR, Lu XC, Lv HY, Yang B, Wang T, Han WD.
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [Abstract] [Full Text] [Related]

  • 12. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
    Linn YC, Yong HX, Niam M, Lim TJ, Chu S, Choong A, Chuah C, Goh YT, Hwang W, Loh Y, Ng HJ, Suck G, Chan M, Koh M.
    Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
    [Abstract] [Full Text] [Related]

  • 13. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
    Tratkiewicz JA, Szer J, Boyd RL.
    Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
    [Abstract] [Full Text] [Related]

  • 14. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS.
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [Abstract] [Full Text] [Related]

  • 15. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells.
    Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V, Prentice HG.
    Br J Haematol; 2002 Jun; 117(4):821-7. PubMed ID: 12060116
    [Abstract] [Full Text] [Related]

  • 16. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
    Foa R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F.
    Blood; 1991 Aug 15; 78(4):1041-6. PubMed ID: 1868239
    [Abstract] [Full Text] [Related]

  • 17. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
    Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A.
    Leukemia; 2005 Dec 15; 19(12):2215-22. PubMed ID: 16224486
    [Abstract] [Full Text] [Related]

  • 18. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL, Amberger DC, Doraneh-Gard F, Sutanto W, Guenther T, Schmohl J, Schuster F, Salih H, Babor F, Borkhardt A, Schmetzer H.
    J Immunother; 2017 Dec 15; 40(6):224-248. PubMed ID: 28557814
    [Abstract] [Full Text] [Related]

  • 19. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
    Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, Christensson B, Dilber MS.
    Hum Immunol; 2001 Oct 15; 62(10):1092-8. PubMed ID: 11600215
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.